2002;72(3):308-318. 165. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insuf ciency. J Crit Care. 2005;20(4):357-363. 166. Douketis J, Cook D, Meade M, et al; Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insuf ciency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med. 2008;168(16):1805-1812. 167. Mah I, Aghassarian M, Drouet L, et al. Tinzaparin and enox- aparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost. 2007;97(4):581- 586. 168. Lindblad B, Borgstr m A, Wake eld TW, Whitehouse WM Jr, Stanley JC. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thromb Res. 1987;48(1):31-40. 169. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial rever- sal of low molecular weight heparin (PK 10169) anti-Xa activ- ity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis. 1986;16(2):139-146. 170. Racanelli A, Fareed J, Walenga JM, Coyne E. Biochemical and pharmacologic studies on the protamine interactions 2012 American College of Chest Physicians by Kimberly Henricks on February 10, 2012 chestjournal.chestpubs.org Downloaded from e42S Parenteral Anticoagulants 205. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356(25):2653-2655. 206. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106(12):3791-3796. 207. Kuo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology. 2005;10(4):271-275. 208. Blackmer AB, Oertel MD, Valgus JM. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues. Ann Pharmacother. 2009;43(10):1636-1646. 209. 